Diagnostic efficacy and safety of gadoteridol compared to gadobutrol and gadoteric acid in a large sample of CNS MRI studies at 1.5 T
| Autor: | Giulia Anello, Clodoaldo Pereira, Sonia Francesca Calloni, Andrea Falini, Paolo Vezzulli, Nicoletta Anzalone, Anna Del Poggio, Antonella Iadanza |
|---|---|
| Přispěvatelé: | Del Poggio, Anna, Anello, Giulia, Calloni, Sonia Francesca, Vezzulli, Paolo, Pereira, Clodoaldo, Iadanza, Antonella, Falini, Andrea, Anzalone, Nicoletta |
| Rok vydání: | 2022 |
| Předmět: |
Adult
Contrast Media Gadolinium Mri studies Malignancy 030218 nuclear medicine & medical imaging Gadobutrol 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Gadolinium-based contrast agents (GBCA) Heterocyclic Compounds Organometallic Compounds medicine Humans Radiology Nuclear Medicine and imaging Adverse effect Aged Radiological and Ultrasound Technology Gadoteridol business.industry Middle Aged medicine.disease Magnetic Resonance Imaging chemistry Central nervous system Cohort Gadoteric acid Neurology (clinical) Nuclear medicine business 030217 neurology & neurosurgery Kappa MRI medicine.drug |
| Zdroj: | Journal of Neuroradiology. 49:73-79 |
| ISSN: | 0150-9861 |
| DOI: | 10.1016/j.neurad.2020.06.005 |
| Popis: | Purpose To evaluate safety and diagnostic accuracy of gadoteridol vs. other macrocyclic gadolinium-based contrast agents (GBCAs) in a large cohort of consecutive and non-selected patients referred for CE-MRI of the CNS. Material and methods Between November 2017 and March 2018, we prospectively enrolled a consecutive cohort of patients referred for neuroradiological CE-MRI (1.5 T MRI). Image quality and adverse events were assessed. Diagnostic performance was determined for a subgroup of patients with truth standard findings available. Comparison was made between patients receiving gadoteridol and patients receiving other macrocyclic GBCAs. Inter-reader agreement (kappa) between two expert neuroradiologists was calculated for the diagnosis of malignancy. Results Overall, 460 patients (220 M/240F; mean age 54 ± 16 years) were enrolled of which 230 received gadoteridol (Group 1) and 230 either gadoteric acid or gadobutrol [n = 83 (36.1%) and n = 147 (63.9%), respectively; Group 2]. Image quality was rated as good or excellent in both groups. The sensitivity, specificity and diagnostic accuracy for determination of malignancy was 88.2%, 96.5% and 95.4%, respectively, for Group 1 and 93.7%, 97.4% and 96.9%, respectively, for Group 2, with no significant differences between groups (P > 0.75) for any determination. Inter-reader agreement for the identification of malignancy was excellent [K = 0.877 (95%CI: 0.758–0.995) and K = 0.818 (95%CI: 0.663–0.972) for groups 1 and 2, respectively; P = 0.0913]. Adverse events occurred in 5 of 460 (1.09%) patients overall, with no significant difference (P = 0.972) between groups. Conclusion Gadoteridol was safe and guaranteed good image quality without significant differences when compared to gadobutrol and gadoteric acid in a wide range of CNS pathologies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect